Fingerprint
Dive into the research topics of 'TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically